No Data
No Data
Express News | Lyra Therapeutics Estimates That It Will Incur Charges Of About $3.9M-$4.1M In Connection With The Workforce Reduction; Expects That The Majority Of Charges Related To Workforce Reduction Will Be Incurred In Q2 Of 2024
Express News | Lyra Therapeutics: Expects That the Majority of Charges Related to Workforce Reduction Will Be Incurred in the Second Quarter of 2024
Express News | Lyra Therapeutics:Estimates That It Will Incur Charges of About $3.9 to $4.1 Million in Connection With the Workforce Reduction
Express News | Trading Halt: Halt Status Updated at 9:40:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Lyra Therapeutics Inc - Reduction in Force Included John E. Bishop, Company's Chief Technology Officer
Express News | Lyra Therapeutics Inc: Measures Are Expected to Extend Lyra's Cash Runway Into 2026
No Data
还是算了 : The most important thing for pharmaceutical companies is research and development. If there are no plans for R&D now, it is chronic death